ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2639

Coronary-Artery Atherosclerosis in Males with Systemic Lupus Erythematosus

Juanita Romero-Díaz1, Sergio Criales-Vera2, Eric Kimura-Hayama2, Roberto Ivan Acosta-Hernandez1, Maricruz Dominguez-Quintana1 and Jorge Sánchez-Guerrero3, 1Immunology and Rheumatology, Instituto Nacional de Ciencias Medicas y Nutricion, Mexico City, Mexico, 2Radiology Department, Instituto Nacional de Cardiologia, Mexico City, Mexico, 3Rheumatology, Mount Sinai Hospital and University Health Network, Toronto Canada, Toronto, ON, Canada

Meeting: 2014 ACR/ARHP Annual Meeting

Keywords: atherosclerosis and risk, Lupus

  • Tweet
  • Email
  • Print
Session Information

Title: Systemic Lupus Erythematosus - Clinical Aspects and Treatment: Epidemiology, Women's Health, Cardiovascular and CNS

Session Type: Abstract Submissions (ACR)

Background/Purpose . Premature coronary-artery atherosclerosis is a major cause of morbidity and mortality in females with systemic lupus erythematosus (SLE), but little is known about the frequency, extent, risk-factors, and burden of coronary-artery disease in male patients.

Methods . We studied 96 male SLE patients attending our outpatient clinic and 94 healthy males w/o preexisting coronary heart disease, matched by age and race. Patients and controls had a standardized assessment of demographic characteristics and traditional cardiovascular risk factors. In addition, patients had an evaluation of lupus characteristics, medications, and laboratory tests including immunological, extended lipid profile, homocystein, and hsCRP. All patients and healthy controls were screened for coronary-artery calcifications using a 64-slice Multidetector Computed Tomography and the extent of calcification was measured by means of the Agatson score.

Results .  Mean (SD) age of lupus patients and controls was 34.9 (10.5) and 35.3 (9.8) years, respectively. Coronary-calcifications were detected in 18 patients (18.8%) and 7 (7.5%) controls (OR 2.87, 95% CI 1.07-8.53). Median calcium score in patients was 68.75 (4.6-755.6), and 7.7 (1.1-140.2) in controls. Calcifications in lupus patients and controls were detected since age 31-40 and 41-50 years, respectively. In two patients, calcifications were detected within 3 years of diagnosis. Patients had more often hypertension (39% vs 4%, P<0.001) and higher levels of homocysteine (14.4+ 10.1 vs 9.3 + 2.5, P<0.001) than controls.

In comparison to patients w/o calcifications, patients with calcifications were older (32.7 + 9.5 vs 44.8 + 7.9 years, P<0.001), had a wider waist (89.1 + 14.4 vs 96.4 + 13.7 cm, P=0.008), higher systolic blood pressure (114.9 + 9.7 vs 121.7 + 12.0, P=0.02), higher Framingham risk score [2.2(1-17) vs 7.9(1-30), P<0.001] and current smokers (14% vs 39%, P=0.04).  Lupus duration was longer (7.1 + 5.7 vs 13.4 + 9.6 years, P=0.01), had accrued more damage (SDI 1.0 + 1.2 vs 2.3 + 1.6, P=0.002), higher cumulative dose of prednisone [20.1 (0-56.1) vs 49.9(8.5-106.5 grams, P=0.001], and received Azathioprine more often (51% vs 78%, P=0.04).  No difference was observed in lupus activity during the course of the disease, clinical manifestations, autoantibodies, and use of anti-malarials and aspirin.

Logistic regression adjusting by disease duration showed an independent association of age (OR 1.23, 95% CI 1.04-1.45) and SLICC score (OR 3.21, 95% CI 1.31-7.86) with calcifications.

Conclusion .  Coronary-artery calcifications are more common, extensive, and present at younger age in male lupus patients than in the general population. Their association to traditional risk-factors and lupus characteristics, particularly chronic damage, raise the possibility of identifying modifiable risk-factors.


Disclosure:

J. Romero-Díaz,
None;

S. Criales-Vera,
None;

E. Kimura-Hayama,
None;

R. I. Acosta-Hernandez,
None;

M. Dominguez-Quintana,
None;

J. Sánchez-Guerrero,
None.

  • Tweet
  • Email
  • Print

« Back to 2014 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/coronary-artery-atherosclerosis-in-males-with-systemic-lupus-erythematosus/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology